Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report

Figure 1 Pelvic magnetic resonance imaging during different treatment stages. A: Tumor site before treatment; B: Lymph node before treatment; C: Tumor site after 2 cycles of treatment; D: Lymph node after 2 cycles of treatment; E: Tumor site after 4 cycles of treatment; F: lymph node after 4 cycles of treatment; G: Tumor site after 2 yr of treatment; H: Lymph node after 2 yr of treatment.

Figure 2 Cystoscopy. A: Cystoscopy before treatment; B: Cystoscopy after 2 cycles of treatment.

Figure 3 Histology of the tumor tissue before treatment. A and B: Representative images show mixed histology of (A) adenocarcinoma and (B) glandular variants by H&E staining (6 × magnification); C: Immunohistochemistry for programmed cell death-ligand 1 expression in bladder cancer tissues (200 × magnification).

Figure 4 Tumor mutational burden in the patient. TMB: Tumor mutational burden.

Figure 5 Timeline of patient treatment. TURBt: Transurethral resection of the bladder tumor; IHC: Immunohistochemical; MRI: Pelvic magnetic resonance imaging.